Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  18.00 4.66% 404.00 4,324 10:03:09
Bid Price Offer Price High Price Low Price Open Price
396.50 405.50 404.00 402.50 403.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.75 -138.78 -13.17 3,008
Last Trade Time Trade Type Trade Size Trade Price Currency
10:28:28 O 3,000 405.32 GBX

Hutchmed (china) (HCM) Latest News (7)

More Hutchmed (china) News
Hutchmed (china) Investors    Hutchmed (china) Takeover Rumours

Hutchmed (china) (HCM) Discussions and Chat

Hutchmed (china) (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:28:30405.323,00012,159.60O
09:05:12405.2814.05O
09:01:36404.002080.80AT
09:00:00402.50129519.23AT
09:00:00402.50171688.28AT
View all Hutchmed (china) trades in real-time

Hutchmed (china) (HCM) Top Chat Posts

DateSubject
18/6/2021
09:20
Hutchmed (china) Daily Update: Hutchmed (china) Limited is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 386p.
Hutchmed (china) Limited has a 4 week average price of 373p and a 12 week average price of 340.50p.
The 1 year high share price is 538p while the 1 year low share price is currently 340.50p.
There are currently 744,515,660 shares in issue and the average daily traded volume is 25,720 shares. The market capitalisation of Hutchmed (china) Limited is £3,007,843,266.40.
01/6/2021
14:57
whatja: Steadied the ship It appears last week’s presentation has firmed up the share price with promises of a rich pipeline to drive a rapid commercialisation phase. There are still lots of regulatory hurdles to clear but the data presented looks promising. The US share price went through $30 a short while ago....the sinking feeling of a few weeks ago seems a distant memory. A doubling of the Market capitalisation with the 2025 targets being met seems quite possible. Atleast that is why I have my holding.
26/5/2021
21:56
cisk: Must admit I'm perplexed here. I've held companies through tough periods, price has halved etc, but the fundamental belief (or not) I've had on a company has determined whether I keep holding. HCM is essentially a Chinese company - in as far as it's market is China. Personally I believe the (stock) market is well aware of this, hence the poor recent performance in its shares. And no amount of seeking HK listing etc will change this. So my confusion stems from why people are so confused about this. It's pretty simple. If you think that the mkt has underpriced the company, it's a buy. If you are concerned about the China situation then maybe it's better to sell. Personally, I believe fundamentally it's a good company, and yes if it was based in the US then the price would be far, far higher. But it's not, so that creates an opportunity in my view. I'm happy to continue to hold in the belief that value will out in the long run. Others of course may have a different view, decide to sell and I wish them luck. NofS, you have made many valuable and interesting posts over the years and know the company better than most. If you think the opportunity cost of holding HCM isn't worth it, then by all means sell. But let's no kid ourselves that there is some magical silver bullet that will suddenly perk up the share price - whilst the company is still China-centric. If they get a drug on the mkt in the RoW then the market will sit up and take notice. It's a big IF but personally I'm happy with the risk / reward here.
11/5/2021
06:43
miti 1000: Nerdofsteel , A lot of biotech stocks are tanking at the moment. Rather than panic , hold your nerve until the company announces some newsflow which you don't like and then sell, if you must. Just cos the share price is falling doesn't seem like a sensible reason to me. As , I've said in the past, the only negative about HCM is that the AZN/SAVO news a few years ago was a good reason to sell the news and no idea why posters on here didnt recognise it as such. Problem was that was the blockbuster hope and that stalled and concerns have not alleviated . Still at this price HCM has other indications that have developed plus the big 100mill investment from a respected fund. Along with that we could have a HK float in the next year. The share price now is near support levels so all in all, I've started buying in , for the 1st time in a few years. just a small 7k buy at the close but I'll average down if necessary . I made a lot of money on HCM on it last time, as you know. Value will out at some point. Ride it out is my advice.
05/4/2021
19:27
steeplejack: I'm becoming increasingly sceptical if there's anything imminent thats going to trigger some damascene experience in the share price fortunes of HCM.There are some very old brooms managing this company,brooms that were employed by Hutchinson Whampoa many years ago.As capable as these old hands maybe,i reflect that fresh management might be more conscious that this is now an independent company,no longer a consolidated subsidiary.The relative underperformance of the NASDAQ over the last three years should be a real cause for concern for a company that's tapping investors from time to time.The investment message simply isn't getting across and that is costing HCM money re dilution.
25/3/2021
09:25
sportii: Not sure the company gives any importance to investors’ interests. Its glaringly true that the market valuation is very very low. Is there another pharma company of this magnitude with such low market valuation? Over the last 5/6 years, on 4-5 occasions, the share price climbed up on a steady pace, backed up by genuinely solid reasons(successful clinical trials, extending operational activities to the USA, enviable pipeline, triple hundred millions of investments by two major funds, drugs getting approved by authorities and subsequent marketing etc., etc.). However, on every occasion, share price failed to maintain the higher valuation longer than few weeks due to various (some times without any) reasons. For example, 6-8 weeks ago, AIM share price was > £5.30 and NYSE ADRs > $37. One fine day, following the announcement of reasonably satisfactory annual results, more than a million ADRs got traded (?sold) which caused severe drop in the share price Surprisingly, the very following day, a million ADRs got (?)bought, with no improvement in the sp! Presently, share price is languishing at £4 (and ADRs $27). The company keeps the news of Asian listing in the circulation as a hope for the investors. Is it a carrot hanging at a distance? Personally, I feel appreciating Hutchmed for the great work of research and development of newer therapies for oncology and immunology which, undoubtedly, will be useful to millions of people. But, as an investor I remain seriously sceptical about poor show in improving market valuation. (PS: no intention of recommending either to buy or sell. Do your own research)
17/3/2021
06:50
sportii: The company had number of ‘breakthrough’ opportunities viz, approval for fruquintinib/ and launching of Elunate/Sulanda. What exactly is the intention behind the precondition of ‘commercialisation success’ for listing at HK/ STAR? There weren’t any such preconditions before listing at London and NYSE. Is the management ‘concernedR17; with a much higher share price? Or, is a lower share price much preferred for some unknown reason?
10/3/2021
13:07
dbadvn: Follow up on call with CH. Tried to cover all your questions , but may have missed a few , anyway in no particular order. 1. Asian listing/ share price/cash flow Share price was probably ahead of the market at end of 2017 . This was followed by 2018 setback of AZN cancelling the Savvanah ( ?) ph3 study .( which turned out to actually be wrong ). 2019 clumsy consolidation by Huchison ( learned lesson , will not sell into market again , only to large 3rd party if at all ). Very recent falls just part of Asian Biotech sell off in general . Even CH feels capitalisation should be around 8-10bn, pipeline not being correctly valued / recognised. Asian listing very much at forefront and cannot say more, But later on had conversation on lining up large investors implying that listing will be within next 9 months. Conditions are aligning. Cash in next 2years will come from large investors , sale of OCI business, improved profits as new drugs get to market . Did not rule out placing but not say would be needed either. Also made the point that large investors ( Fidelity etc) were very pleased with results and progress . Selling down has been by early investors who have lightened their positions and mainly by Far East groups ( Mitsui). 2. AZN Relationship / JUnshi deal etc Had to really hold Azn feet to the fire but they are now responding ( Eli Lilly much worse , very relieved to be out of that deal ) especially in China. Assuming Savo approval By Q3 they will have 2000 reps selling ( what? - did not understand this ) . Should bring in $250m at 30% royalty in 2022. Azn/ Junshi not of particular concern , not really competition as different drug market . Tagrisso/Savo combo outside of China now moving ahead at good pace. 3. Inmagene deal. Need to concentrate of Oncology development Immunology is a very different market . Requires a completely different team and a long term approach ( long term ongoing treatment so drugs must have low / no toxicity , large placebo effect ) Inmagene only have options up to Ind stage so not given too much away but saved the expenditure and the distraction . Not v clear on savings but probably North of $200m) depending on success of asset. Inmagene execs are ex HCM but almost every Biotech in China has ex HCM execs as they have been around so long. Team is very well connected to industry bodies in China , 4 Patient access programme in US/Can ? Not possible without full approval. In China non approved drugs can be used at Doctor's discretion , "off label", but not allowed to actively market a drug before approval ( hence large conferences = pseudo marketing) 5. Seroquel - no mention sorry. 6. Leveraging sales by doing deals with Multinationals. Being approached all the time to sell on behalf of Multinatiuonal in China , and sell licence to Multinational outside China. Open minded , if the deal is right then may do it but so far experience with Eli Lilly and Azn has not really encouraged them in this direction. Knows Beigene CEO very well ( partnered with Surafatinib). This was a fantastic deal for Beigene especially as they were behind in the market compared to Merck/ Pfizer/ Roche. Still it was a one time plug , gave away huge forward revenue stream . 7 Future. Getting more and more excited by 689 , extraordinary results ( also large market). 523 and 306 also coming along better than expected . 453 - back burner due to toxicity. 8 Overall - CH recognises investor frustration but insists that barring extraordinary events next 12 months should be a "very exciting time " for investors. Thats it. D
28/12/2020
15:20
steeplejack: Hutchison China MediTech (HCM)Last but not least is a $4 billion holding company in China's drug manufacturing sector. Hutchison China MediTech, doing business as Chi-Med, owns a group of subsidiaries engaged in the manufacture and distribution of pharmaceuticals. HCM's products include over the counter medications and consumer healthcare items, as well as sophisticated therapeutics and immunotherapies for the treatment of cancer and autoimmune disorders.As with many pharmaceutical companies, HCM's share price is driven by the company's approved products and development pipeline. In this area, HCM has two advantages.First advantage is Elunate, a drug approved by Chinese regulators as a treatment for colorectal cancer. The company has been working with Eli Lilly, one of the giants of Big Pharma, to fast-track marketing and patient access; earlier this year, that agreement was amended to improve commercialization efforts on Elunate to include all of China.The second advantage is Savolitinib, a drug developed as a treatment for some types of non-small cell lung cancer. The company's New Drug Application (NDA), a key milestone in regulatory approval, has been accepted by China's National Medical Products Administration.Both drugs are being investigated for additional indications, and are part of an active pipeline at the company, which includes nine medications in various stages of development.Among the fans is Deutsche Bank analyst Rajan Sharma who rates HCM a Buy. His $40 price target shows the extent of his confidence, implying ~37% upside for the coming year. (To watch Sharma's track record, click here)Defending his bullish stance on HCM, Sharma writes, "We believe Chi-Med is well on track in its evolution from a Chinese pharmaceutical/OTC company into a fully integrated, innovative global oncology company [...] We see the next steps of Chi-Med's evolution as being approval of its first solely developed drug and launches outside of China, particularly in the US. The company is on track to achieve both of these in the next two years."All in all, HCM has earned a Moderate Buy consensus rating, with 2 Buy reviews in the past three months. Shares are priced at $29.28 and the $40 average price target matches Sharma's. (See HCM stock analysis on TipRanks)
27/12/2020
14:34
miti 1000: Having sold out at the highs of 550 a few years back when MSCI china funds had to buy the stock, I thought I'd revisit hcm. Long term posters(Matt) moan about moving the listing (FFS, its already on 2 indices!!Get a grip, man) and others simply just chose to ignore Savo/Tagrisso and the lack of an interim readout. Despite the huge bullishness on here , lets be honest, Savolitinib which is what controls the share price has just not progressed as the company wished( remember it failed in one indication 3 years ago) but luckily , the share price rose cos of the aforementioned fund buying allowing me a great exit. There has been been no interim readout of data in combination with Tagrisso.In fact, it has now been called an 'Internal' readout so clearly there appears to be issues in the poster child killer application and indicates things are not progressing to plan . I presume they will have to come out with proper details in 2021 and either the share price will halve or it will go thru the roof if it works after tweaks. This explains why the share price ash gone nowhere but lower since I sold despite such huge gains elsewhere in the sector. I made a huge gain last time on HCM but I'm just not tempted this time even after a 30% fall since I sold almost 3 years. Hard to invest in big size on such a binary bet when the signs don't seem promising on savo/tagrisso.
03/12/2020
14:16
dbadvn: HCM share price , lacking the ridiculous hype surrounding other biotechs, and any takeover premium , will follow the numbers. It will start to rocket as soon as the market sees the cash being thrown off in the next few years as sales rise rapidly.
Hutchmed (china) share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
HCM
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 10:01:34